Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

By D. Tenney, R. Rose, Carl J. Baldick, K. Pokornowski, Betsy J. Eggers, Jie Fang, Michael Wichroski, Dong Xu, Joanna Y Yang, R. Wilber and 1 more. Hepatology, 2009

796 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/1afee52fb9e06bf66e33c9cb10cf38d1f6744f21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. RS Brown
2. JB Wong
3. NA Terrault
4. M. Jonas
5. B. McMahon
6. NH Bzowej
7. JP Hwang
8. A. Lok

Citations in the corpus

• Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “Thus, although entecavir monotherapy has a low rate of drug resistance in NA-na€ıve patients (approximately 1% after 5 years of treatment),((223)) it has a high rate of resistance in lamivudine-refractory patients (approximately 50% after 5 years of treatment).”